【摘要】：目的:探討白蛋白結(jié)合型紫杉醇(PTX)與PTX脂質(zhì)體(力撲素)治療復(fù)發(fā)性卵巢癌的近期療效及不良反應(yīng)。方法:回顧性分析采用PTX治療的90例復(fù)發(fā)性卵巢癌患者的臨床資料,其中應(yīng)用白蛋白結(jié)合型PTX聯(lián)合奈達(dá)鉑治療30例為PTX結(jié)合型組,應(yīng)用PTX脂質(zhì)體聯(lián)合奈達(dá)鉑治療60例為PTX脂質(zhì)體組。比較兩組癌抗原125(CA125)下降情況和腫瘤病灶縮小情況,以及不良反應(yīng)的差異。結(jié)果:PTX結(jié)合型組CA125下降的有效率(63.3%)高于PTX脂質(zhì)體組(41.7%);PTX結(jié)合型組病灶縮小的有效率(54.5%)高于PTX脂質(zhì)體組(23.8%),差異均有統(tǒng)計學(xué)意義(P0.05)。PTX結(jié)合型組腹瀉、嘔吐、白細(xì)胞減少Ⅲ~Ⅳ級的不良反應(yīng)發(fā)生率均少于PTX脂質(zhì)體組(P0.05),兩組神經(jīng)毒性發(fā)生率比較,差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:白蛋白結(jié)合型PTX聯(lián)合奈達(dá)鉑與PTX脂質(zhì)體聯(lián)合奈達(dá)鉑治療復(fù)發(fā)性卵巢癌相比,其臨床近期療效提高,嚴(yán)重不良反應(yīng)率較低,使用方便,值得推廣。
[Abstract]:Aim: to investigate the efficacy and side effects of albumin bound paclitaxel (PTX) and PTX liposome (telopontin) in the treatment of recurrent ovarian cancer. Methods: the clinical data of 90 patients with recurrent ovarian cancer treated with PTX were retrospectively analyzed. 30 patients were treated with albumin binding PTX combined with nedatin. 30 patients were treated with PTX binding type. 60 cases were treated with PTX liposome combined with niedaplatin as PTX liposome group. The decrease of cancer antigen 125 (CA125) and the reduction of tumor focus, and the difference of adverse reactions were compared between the two groups. Results the effective rate of CA125 reduction in the CA125 binding group (63.3%) was higher than that in the PTX liposome group (41.7%), and the effective rate of lesion reduction in the PTX-binding group (54.5%) was higher than that in the PTX liposome group (23.8%). The difference was statistically significant (P0.05). The incidence of adverse reactions in grade 鈪，

本文編號：2204455